Welcome to our dedicated page for Verve Therapeutics SEC filings (Ticker: VERV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Verve Therapeutics’ gene-editing disclosures can feel like wading through a lab notebook written in legalese. Risk factors span emerging CRISPR regulations, manufacturing hurdles and multi-million-dollar collaboration terms—details scattered across 300-page 10-Ks and frequent 8-Ks after clinical readouts. If you have ever asked, “Where can I find Verve Therapeutics’ quarterly earnings report 10-Q filing?” or needed Verve Therapeutics insider trading Form 4 transactions before a pivotal PCSK9 data drop, this page ends the search.
Stock Titan’s platform pairs every VERV submission—10-K, 10-Q, 8-K, DEF 14A, S-1 and more—with AI-powered summaries that explain trial milestones, cash runway shifts and licensing economics in plain English. Our engine flags Verve Therapeutics Form 4 insider transactions real-time, highlights executive stock awards in the proxy statement, and answers natural questions like “What does Verve report about ANGPTL3 safety?” With instant alerts, you see each filing the moment it hits EDGAR, then skim concise AI notes instead of scrolling hundreds of footnotes.
Use this hub to: monitor management’s conviction through insider buys, compare R&D spending across quarters, track 8-K material events explained such as FDA clearances, and read a Verve Therapeutics annual report 10-K simplified section that links pipeline timelines to financial forecasts. Whether you’re studying understanding Verve Therapeutics SEC documents with AI for diligence or checking a Verve Therapeutics proxy statement executive compensation discussion, our coverage delivers every detail investors need—no biotech PhD required.
Verve Therapeutics, Inc. (NASDAQ: VERV) filed Post-Effective Amendment No. 3 to its automatic shelf registration (Form S-3, File No. 333-267578) to terminate the registration and deregister all unsold securities previously available under the shelf.
- The original shelf (effective Sept 23 2022) covered up to $500 million in mixed securities and an additional $150 million of common stock under an at-the-market sale agreement with Jefferies.
- On July 25 2025, Verve completed its merger with Eli Lilly and Company; Ridgeway Acquisition Corp. was merged into Verve, which now operates as an indirect wholly owned subsidiary of Lilly.
- Because the company is no longer an independent public issuer, all offerings under the shelf have been permanently terminated.
Verve Therapeutics, Inc. ("Verve") filed Post-Effective Amendment No. 1 to five previously effective Form S-8 registration statements that in aggregate covered approximately 31.2 million shares of common stock reserved for the company’s 2018 Equity Incentive Plan, 2021 Stock Incentive Plan, Amended & Restated 2021 Employee Stock Purchase Plan, and 2024 Inducement Stock Incentive Plan.
On 25 July 2025, Verve completed its merger with Eli Lilly and Company through Ridgeway Acquisition Corporation and is now an indirect, wholly-owned Lilly subsidiary. Because Verve will no longer issue shares to the public, it has terminated all offerings under the S-8s and is deregistering any unsold shares that remained available under the equity plans. After effectiveness of these amendments, no Verve securities remain registered with the SEC pursuant to the referenced S-8 filings.
The document is purely administrative: it does not introduce new financing, earnings data, or changes to plan terms. It simply formalises the cleanup of outstanding share registrations following the closing of the Lilly transaction.
Verve Therapeutics, Inc. (VERV) has filed Post-Effective Amendment No. 1 to each of its five outstanding Form S-8 registration statements. The amendments formally deregister all unsold shares—originally up to roughly 31.18 million shares reserved for the 2018 Equity Incentive Plan, 2021 Stock Incentive Plan, Amended & Restated 2021 ESPP and the 2024 Inducement Plan.
The administrative action follows the 25 July 2025 closing of the merger under which Ridgeway Acquisition Corp., a subsidiary of Eli Lilly & Co., merged with Verve. Verve survives as an indirect, wholly owned Lilly subsidiary, and all public offerings of its common stock have been terminated. In line with undertakings in each S-8, the company is required to remove from registration any securities that remained unsold once the plans ceased to issue shares.
Investor impact: The filing is procedural, confirming that no Verve equity will be issued post-merger. It eliminates potential future dilution but does not alter the economic terms previously agreed for shareholders in the Lilly acquisition.
FAQ
What is the current stock price of Verve Therapeutics (VERV)?
What is the market cap of Verve Therapeutics (VERV)?
